AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™
Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach AUCKLAND, New Zealand, Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an exclusive ag...
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today ann...
AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met
AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and ...
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...
FIRST CLINICAL EVIDENCE PUBLISHED ON AROA's ENIVO™ SYSTEM FOR SURGICAL DEAD SPACE MANAGEMENT.
AUCKLAND, New Zealand, Aug. 27, 2025 /PRNewswire/ -- AROA is pleased to announce the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitledProspective, First-in-Human Clinical Evaluation of a Novel Tissue ...
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration
company, Aroa Biosurgery, is pleased to announce a milestone in clinical
evidence.
New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.
AUCKLAND, New Zealand, Jan. 17, 2025 /PRNewswire/ -- New Zealand headquartered soft tissue regeneration company Aroa Biosurgery recently announced the publication of further strong clinical evidence reinforcing both efficacy and cost benefits of its AROA ECM™ technology when used in high-risk lim...
INTERNATIONAL COLLABORATION AIMS TO COMBAT DIABETES EPIDEMIC IN THE SOUTH PACIFIC
AUCKLAND, New Zealand, Aug. 21, 2024 /PRNewswire/ -- Headquartered in Auckland,
New Zealand, Aroa Biosurgery is a global soft tissue reconstruction company
which develops and manufactures wound care and surgical products to improve
healing in complex wounds and soft tissue reconstruction.
AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS
AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivere...
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft
tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the
appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr
as a Non-Executive Director to the board.
